
First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
Nuzrya (omadacycline, Paratek®)
Indications: Adult patients with Counity-acquired bacterial pneumonia (CAPB) or acute bacterial skin and skin structure infections (ABSSI)
Dosage:
Contraindications: Known hypersensitivity to omadacycline, tetracycline-class antibacterial drugs or any of the excipients in NUZYRA
Click here for mor



